Mirum Pharmaceuticals, Inc. shows strong growth with a 43% revenue jump and promising pipeline assets. Click here for my ...
7d
Zacks Investment Research on MSNMirum's Heavy Dependence on Livmarli for Revenues Remains a WoeMirum Pharmaceuticals’ MIRM lead product, Livmarli (maralixibat), an orally administered ileal bile acid transporter (“IBAT”) ...
Hosted on MSN2mon
Bile acids impair liver cancer immunotherapy: A dietary supplement may offer reliefMore information: Siva Karthik Varanasi et al, Bile acid synthesis impedes tumor-specific T cell responses during liver cancer, Science (2025). DOI: 10.1126/science.adl4100 ...
Bile acids were first described chemically in 1849 ... This description included the final step of their synthesis — the conjugation of the amino acids taurine or glycine by our liver.
Previous studies of the bile acid composition of meconium and bile obtained in the first few days of life indicate that, compared to the adult, there are significant differences in the hepatic ...
13d
News-Medical.Net on MSNSemi-synthetic bile acid could be a promising therapeutic option for TH17-mediated intestinal diseasesA research team from the Medical University of Vienna has made further progress in the treatment of intestinal inflammation.
A research team has made further progress in the treatment of intestinal inflammation. A study shows that the semi-synthetic bile acid NorUDCA inhibits in the intestine the formation of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results